Arrowhead Historical Income Statement

ARWR Stock

USD 26.15 5.10 24.23%

Historical analysis of Arrowhead Pharmaceuticals income statement accounts such as Interest Expense of 30.7 M, Selling General Administrative of 93.8 M or Selling And Marketing Expenses of 1.8 M can show how well Arrowhead Pharmaceuticals performed in making a profits. Evaluating Arrowhead Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Arrowhead Pharmaceuticals's future profits or losses.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Arrowhead Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Arrowhead Pharmaceuticals is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arrowhead Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing.

To learn how to invest in Arrowhead Stock, please use our How to Invest in Arrowhead Pharmaceuticals guide.

About Arrowhead Income Statement Analysis

Arrowhead Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Arrowhead Pharmaceuticals shareholders. The income statement also shows Arrowhead investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Arrowhead Pharmaceuticals Income Statement Chart

At this time, Arrowhead Pharmaceuticals' Tax Provision is relatively stable compared to the past year. As of 11/29/2024, Interest Income is likely to grow to about 18.5 M, while Selling General Administrative is likely to drop slightly above 93.8 M.

Selling General Administrative Selling And Marketing Expenses Total Revenue Gross Profit Non Recurring Reconciled Depreciation

Total Revenue

Total revenue comprises all receipts Arrowhead Pharmaceuticals generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Arrowhead Pharmaceuticals minus its cost of goods sold. It is profit before Arrowhead Pharmaceuticals operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Most accounts from Arrowhead Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Arrowhead Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arrowhead Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing.

To learn how to invest in Arrowhead Stock, please use our How to Invest in Arrowhead Pharmaceuticals guide.At this time, Arrowhead Pharmaceuticals' Tax Provision is relatively stable compared to the past year. As of 11/29/2024, Interest Income is likely to grow to about 18.5 M, while Selling General Administrative is likely to drop slightly above 93.8 M.

	2021	2022	2023	2024 (projected)
Gross Profit	243.2M	240.7M	3.6M	3.4M
Total Revenue	243.2M	240.7M	3.6M	3.4M

Gross Profit Total Revenue

Arrowhead Pharmaceuticals income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Selling And Marketing Expenses	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Research Development	Discontinued Operations	Net Income From Continuing Ops	Non Operating Income Net Other	Minority Interest	Non Recurring	Tax Provision	Interest Income	Net Interest Income	Reconciled Depreciation
Depreciation And Amortization		-0.11	0.9	0.44	0.42	0.42	0.98	-0.86	-0.81	-0.8	-0.33	0.98	-0.86	0.21	-0.86	-0.27	0.98	-0.34	-0.82	0.37	0.85	-0.26	0.88	0.86	-0.25	0.86
Interest Expense	-0.11		-0.13	0.09	0.23	0.23	-0.15	0.27	0.32	0.33	-0.2	-0.15	0.28	0.54	0.28	-0.1	-0.15	-0.13	0.37	-0.05	-0.19	-0.05	-0.27	-0.05	0.72	-0.23
Selling General Administrative	0.9	-0.13		0.43	0.58	0.58	0.91	-0.73	-0.89	-0.88	-0.3	0.91	-0.72	0.32	-0.72	-0.1	0.87	-0.36	-0.87	0.37	0.64	-0.14	0.87	0.66	-0.05	0.86
Selling And Marketing Expenses	0.44	0.09	0.43		0.14	0.14	0.38	-0.35	-0.37	-0.36	0.26	0.38	-0.35	0.05	-0.35	-0.12	0.36	-0.99	-0.35	-0.08	0.26	0.03	0.26	0.26	-0.01	0.28
Total Revenue	0.42	0.23	0.58	0.14		1.0	0.36	0.06	-0.35	-0.33	-0.45	0.36	0.07	0.53	0.06	0.38	0.31	-0.19	-0.31	0.22	0.1	-0.19	0.42	0.22	0.43	0.47
Gross Profit	0.42	0.23	0.58	0.14	1.0		0.36	0.06	-0.35	-0.33	-0.45	0.36	0.07	0.53	0.06	0.38	0.31	-0.19	-0.31	0.22	0.1	-0.19	0.42	0.22	0.43	0.47
Other Operating Expenses	0.98	-0.15	0.91	0.38	0.36	0.36		-0.91	-0.83	-0.81	-0.36	1.0	-0.91	0.15	-0.91	-0.29	1.0	-0.26	-0.84	0.33	0.88	-0.19	0.91	0.89	-0.29	0.87
Operating Income	-0.86	0.27	-0.73	-0.35	0.06	0.06	-0.91		0.74	0.73	0.19	-0.91	1.0	0.07	1.0	0.48	-0.93	0.2	0.78	-0.26	-0.89	0.11	-0.79	-0.85	0.5	-0.75
Ebit	-0.81	0.32	-0.89	-0.37	-0.35	-0.35	-0.83	0.74		1.0	0.1	-0.83	0.74	-0.14	0.74	0.11	-0.8	0.3	0.99	-0.38	-0.66	-0.03	-0.76	-0.6	0.26	-0.82
Ebitda	-0.8	0.33	-0.88	-0.36	-0.33	-0.33	-0.81	0.73	1.0		0.08	-0.81	0.73	-0.13	0.73	0.11	-0.78	0.3	0.99	-0.38	-0.65	-0.05	-0.74	-0.58	0.26	-0.8
Cost Of Revenue	-0.33	-0.2	-0.3	0.26	-0.45	-0.45	-0.36	0.19	0.1	0.08		-0.36	0.19	-0.2	0.19	-0.16	-0.37	-0.3	0.12	0.12	-0.3	0.49	-0.37	-0.48	-0.23	-0.43
Total Operating Expenses	0.98	-0.15	0.91	0.38	0.36	0.36	1.0	-0.91	-0.83	-0.81	-0.36		-0.91	0.15	-0.91	-0.29	1.0	-0.26	-0.84	0.33	0.88	-0.19	0.91	0.89	-0.29	0.87
Income Before Tax	-0.86	0.28	-0.72	-0.35	0.07	0.07	-0.91	1.0	0.74	0.73	0.19	-0.91		0.1	1.0	0.47	-0.92	0.2	0.78	-0.24	-0.89	0.12	-0.78	-0.85	0.51	-0.75
Total Other Income Expense Net	0.21	0.54	0.32	0.05	0.53	0.53	0.15	0.07	-0.14	-0.13	-0.2	0.15	0.1		0.09	-0.2	0.12	-0.08	-0.03	0.67	-0.16	0.13	0.01	-0.01	0.73	0.09
Net Income	-0.86	0.28	-0.72	-0.35	0.06	0.06	-0.91	1.0	0.74	0.73	0.19	-0.91	1.0	0.09		0.47	-0.92	0.2	0.78	-0.24	-0.89	0.12	-0.79	-0.85	0.51	-0.75
Income Tax Expense	-0.27	-0.1	-0.1	-0.12	0.38	0.38	-0.29	0.48	0.11	0.11	-0.16	-0.29	0.47	-0.2	0.47		-0.32	0.02	0.11	-0.46	-0.37	-0.03	-0.06	-0.33	0.17	-0.09
Research Development	0.98	-0.15	0.87	0.36	0.31	0.31	1.0	-0.93	-0.8	-0.78	-0.37	1.0	-0.92	0.12	-0.92	-0.32		-0.23	-0.82	0.32	0.9	-0.2	0.9	0.92	-0.33	0.86
Discontinued Operations	-0.34	-0.13	-0.36	-0.99	-0.19	-0.19	-0.26	0.2	0.3	0.3	-0.3	-0.26	0.2	-0.08	0.2	0.02	-0.23		0.27	0.12	-0.12	-0.06	-0.16	-0.13	-0.08	-0.18
Net Income From Continuing Ops	-0.82	0.37	-0.87	-0.35	-0.31	-0.31	-0.84	0.78	0.99	0.99	0.12	-0.84	0.78	-0.03	0.78	0.11	-0.82	0.27		-0.31	-0.72	0.01	-0.78	-0.65	0.35	-0.84
Non Operating Income Net Other	0.37	-0.05	0.37	-0.08	0.22	0.22	0.33	-0.26	-0.38	-0.38	0.12	0.33	-0.24	0.67	-0.24	-0.46	0.32	0.12	-0.31		0.19	0.32	0.23	0.18	0.01	0.28
Minority Interest	0.85	-0.19	0.64	0.26	0.1	0.1	0.88	-0.89	-0.66	-0.65	-0.3	0.88	-0.89	-0.16	-0.89	-0.37	0.9	-0.12	-0.72	0.19		-0.19	0.76	0.96	-0.58	0.77
Non Recurring	-0.26	-0.05	-0.14	0.03	-0.19	-0.19	-0.19	0.11	-0.03	-0.05	0.49	-0.19	0.12	0.13	0.12	-0.03	-0.2	-0.06	0.01	0.32	-0.19		-0.2	-0.18	-0.06	-0.21
Tax Provision	0.88	-0.27	0.87	0.26	0.42	0.42	0.91	-0.79	-0.76	-0.74	-0.37	0.91	-0.78	0.01	-0.79	-0.06	0.9	-0.16	-0.78	0.23	0.76	-0.2		0.77	-0.36	0.84
Interest Income	0.86	-0.05	0.66	0.26	0.22	0.22	0.89	-0.85	-0.6	-0.58	-0.48	0.89	-0.85	-0.01	-0.85	-0.33	0.92	-0.13	-0.65	0.18	0.96	-0.18	0.77		-0.41	0.78
Net Interest Income	-0.25	0.72	-0.05	-0.01	0.43	0.43	-0.29	0.5	0.26	0.26	-0.23	-0.29	0.51	0.73	0.51	0.17	-0.33	-0.08	0.35	0.01	-0.58	-0.06	-0.36	-0.41		-0.29
Reconciled Depreciation	0.86	-0.23	0.86	0.28	0.47	0.47	0.87	-0.75	-0.82	-0.8	-0.43	0.87	-0.75	0.09	-0.75	-0.09	0.86	-0.18	-0.84	0.28	0.77	-0.21	0.84	0.78	-0.29

Click cells to compare fundamentals

Arrowhead Pharmaceuticals Account Relationship Matchups

Arrowhead Pharmaceuticals income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	5.9M	8.3M	10.4M	12.5M	14.4M	15.1M
Interest Expense	9.2B	6.1M	5.0M	18.3M	32.4M	30.7M
Selling General Administrative	52.3M	81.0M	124.4M	90.9M	98.8M	93.8M
Total Revenue	88.0M	138.3M	243.2M	240.7M	3.6M	3.4M
Gross Profit	88.0M	138.3M	243.2M	240.7M	3.6M	3.4M
Other Operating Expenses	181.2M	287.3M	421.7M	445.7M	604.6M	634.9M
Operating Income	(93.2M)	(149.0M)	(178.5M)	(205.0M)	(601.1M)	(571.0M)
Ebit	(93.2M)	(140.8M)	(178.5M)	(188.2M)	(169.3M)	(160.9M)
Ebitda	(87.2M)	(132.6M)	(168.1M)	(175.7M)	(158.1M)	(150.2M)
Total Operating Expenses	181.2M	287.3M	421.7M	445.7M	604.6M	634.9M
Income Before Tax	(84.6M)	(140.8M)	(172.7M)	(206.5M)	(602.3M)	(572.1M)
Total Other Income Expense Net	8.6M	8.2M	5.8M	(1.5M)	(1.2M)	(1.1M)
Net Income	(84.6M)	(140.8M)	(176.5M)	(205.3M)	(599.5M)	(569.5M)
Research Development	128.9M	206.3M	297.3M	353.2M	505.9M	531.2M
Net Income From Continuing Ops	(84.6M)	(140.8M)	(172.7M)	(209.3M)	(188.3M)	(178.9M)
Net Income Applicable To Common Shares	(84.6M)	(140.8M)	(176.1M)	(205.3M)	(184.7M)	(175.5M)
Net Interest Income	9.2M	6.1M	5.0M	(3.0M)	(3.5M)	(3.3M)
Reconciled Depreciation	5.9M	8.3M	10.4M	12.5M	14.4M	8.0M

Pair Trading with Arrowhead Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Arrowhead Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Arrowhead Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against Arrowhead Stock

0.45	BHC	Bausch Health Companies	Pair Corr
0.36	EWTX	Edgewise Therapeutics	Pair Corr
0.36	GANX	Gain Therapeutics	Pair Corr
0.34	HCM	HUTCHMED DRC	Pair Corr

The ability to find closely correlated positions to Arrowhead Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Arrowhead Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Arrowhead Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Arrowhead Pharmaceuticals to buy it.

The correlation of Arrowhead Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Arrowhead Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Arrowhead Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Arrowhead Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Arrowhead Stock Analysis

When running Arrowhead Pharmaceuticals' price analysis, check to measure Arrowhead Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arrowhead Pharmaceuticals is operating at the current time. Most of Arrowhead Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Arrowhead Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arrowhead Pharmaceuticals' price. Additionally, you may evaluate how the addition of Arrowhead Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Arrowhead Historical Income Statement

About Arrowhead Income Statement Analysis

Arrowhead Pharmaceuticals Income Statement Chart

Total Revenue

Gross Profit

Arrowhead Pharmaceuticals income statement Correlations

Arrowhead Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Arrowhead Pharmaceuticals income statement Accounts

Pair Trading with Arrowhead Pharmaceuticals

Moving against Arrowhead Stock

Additional Tools for Arrowhead Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Gross Profit	+ 1.0	Total Revenue
Total Operating Expenses	+ 1.0	Other Operating Expenses
Research Development	+ 1.0	Other Operating Expenses
Income Before Tax	+ 1.0	Operating Income
Net Income	+ 1.0	Operating Income
Ebitda	+ 1.0	Ebit

Discontinued Operations	- 0.99	Selling And Marketing Expenses
Research Development	- 0.93	Operating Income
Research Development	- 0.92	Net Income
Research Development	- 0.92	Income Before Tax
Net Income	- 0.91	Total Operating Expenses
Income Before Tax	- 0.91	Total Operating Expenses